Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. vascular flow
Show results for
Products
Services

Companies

News
Downloads
Videos

Refine by
Date

  • Older

Vascular Flow Articles & Analysis

5 news found

Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis

Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis

Already in the first stages of the disease, patients are affected by episodes of reduced blood flow in fingers and toes. The episodes, known as Raynaud's phenomenon, are often followed by very painful and difficult-to-heal digital ulcers (ulcers of the fingers and toes). ...

ByGesynta Pharma AB


Gesynta Pharma`s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for the treatment of systemic sclerosis

Gesynta Pharma`s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for the treatment of systemic sclerosis

Already at an early stage of the disease, patients suffer from episodes of impaired blood flow in the fingers and toes, Raynaud's phenomenon, which in the course of the disease often lead to very painful, difficult-to-heal, and frequently disabling ulcers. ...

ByGesynta Pharma AB


Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

The study investigates the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral vascular blood flow. Top-line data is expected in Q1/2022. Coordinating Investigator Professor Ariane Herrick, The University of Manchester Centre for Musculoskeletal Research commented: "Systemic sclerosis is a chronic, autoimmune disease that leads to ...

ByGesynta Pharma AB


Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis

Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis

In the first stage, attacks of reduced blood flow to the fingers and toes (Raynaud's phenomenon) occur, which causes pain and impaired fine motor skills. ...

ByGesynta Pharma AB


Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination

Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination

The Cellvizio®100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries Mauna Kea Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Cellvizio® 100 series and all associated Confocal ...

ByMauna Kea Technologies

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT